AML/MDS

1
Pipeline Programs
1
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Senti Biosciences
Senti BiosciencesCA - South SF
1 program
1
SENTI-202Phase 11 trial
Active Trials
NCT06325748Active Not RecruitingEst. Aug 2040

Trial Timeline

Clinical trial activity over time

2024
2025
2026
2027
2028
2029
2030
2031
Senti BiosciencesSENTI-202

Clinical Trials (1)

NCT06325748Senti BiosciencesSENTI-202

SENTI-202: Off-the-shelf Logic Gated CAR NK Cell Therapy in Adults With CD33 and/or FLT3 Blood Cancers Including AML/MDS

Start: Apr 2024Est. completion: Aug 2040
Phase 1Active Not Recruiting

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 companies competing in this space